• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.

作者信息

Gentile Massimo, Morabito Fortunato, Del Poeta Giovanni, Mauro Francesca Romana, Reda Gianluigi, Sportoletti Paolo, Laurenti Luca, Coscia Marta, Herishanu Yair, Recchia Anna Grazia, Varettoni Marzia, Murru Roberta, Chiarenza Annalisa, Condoluci Adalgisa, Moia Riccardo, Pietrasanta Daniela, Loseto Giacomo, Consoli Ugo, Scortechini Ilaria, Rossi Francesca Maria, Zucchetto Antonella, Fraticelli Vincenzo, Vigna Ernesto, Botta Cirino, Tripepi Giovanni, Arrigo Graziella D', Rago Angela, Angeletti Ilaria, Biagi Annalisa, Del Giudice Ilaria, Bomben Riccardo, Rigolin Gian Matteo, Rossi Davide, Di Raimondo Francesco, Gaidano Gianluca, Polliack Aaron, Cuneo Antonio, Foà Robin, Gattei Valter

机构信息

Hematology Unit AO of Cosenza, Cosenza, Italy.

Biothecnology Research Unit, AO of Cosenza, Cosenza, Italy.

出版信息

Leukemia. 2021 Jan;35(1):235-238. doi: 10.1038/s41375-020-0833-x. Epub 2020 Apr 14.

DOI:10.1038/s41375-020-0833-x
PMID:32286543
Abstract
摘要

相似文献

1
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.接受依鲁替尼治疗的真实世界复发/难治性慢性淋巴细胞白血病患者的生存风险评分。一项校园慢性淋巴细胞白血病研究。
Leukemia. 2021 Jan;35(1):235-238. doi: 10.1038/s41375-020-0833-x. Epub 2020 Apr 14.
2
Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.接受依鲁替尼治疗的慢性淋巴细胞白血病患者的预后模型：比较性能分析结果
Eur J Haematol. 2021 Mar;106(3):425-427. doi: 10.1111/ejh.13548. Epub 2020 Nov 29.
3
Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.伊布替尼作为慢性淋巴细胞白血病的初始治疗：一项系统评价和荟萃分析。
Eur J Haematol. 2020 May;104(5):512-515. doi: 10.1111/ejh.13387. Epub 2020 Feb 22.
4
Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.伊布替尼治疗复发/难治性慢性淋巴细胞白血病患者中选择基因突变的预测意义。
Eur J Haematol. 2021 Mar;106(3):320-326. doi: 10.1111/ejh.13550. Epub 2020 Dec 19.
5
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.苯达莫司汀和利妥昔单抗在未经治疗的先前不适合的慢性淋巴细胞白血病患者中的疗效。在真实环境中与伊布替尼的间接比较。一项 GIMEMA-ERIC 和美国的研究。
Cancer Med. 2020 Nov;9(22):8468-8479. doi: 10.1002/cam4.3470. Epub 2020 Sep 24.
6
Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib.205 例慢性淋巴细胞白血病患者接受伊布替尼治疗的真实世界结果。
Eur J Haematol. 2020 Nov;105(5):646-654. doi: 10.1111/ejh.13499. Epub 2020 Aug 26.
7
Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.真实世界中伊布替尼在慢性淋巴细胞白血病中的剂量减少、暂停和停药。
Future Oncol. 2021 Dec;17(35):4959-4969. doi: 10.2217/fon-2021-0964. Epub 2021 Nov 16.
8
Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.依鲁替尼治疗慢性淋巴细胞白血病患者过程中出现的乙型肝炎病毒再激活
Turk J Haematol. 2020 Aug 28;37(3):208-209. doi: 10.4274/tjh.galenos.2020.2019.0180. Epub 2020 Apr 6.
9
Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.依鲁替尼诱发慢性淋巴细胞白血病患者的心包填塞
Turk J Haematol. 2021 Feb 25;38(1):83-85. doi: 10.4274/tjh.galenos.2020.2020.0446. Epub 2020 Nov 9.
10
Ibrutinib-Induced Skin Rash.依鲁替尼引起的皮疹
Turk J Haematol. 2021 Feb 25;38(1):81-83. doi: 10.4274/tjh.galenos.2020.2020.0120. Epub 2020 Oct 15.

引用本文的文献

1
Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs.慢性淋巴细胞白血病：新药时代的预后因素
Cancers (Basel). 2024 Jul 31;16(15):2732. doi: 10.3390/cancers16152732.
2
B Cell Subsets and Immune Checkpoint Expression in Patients with Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病患者的B细胞亚群与免疫检查点表达
Curr Issues Mol Biol. 2024 Feb 23;46(3):1731-1740. doi: 10.3390/cimb46030112.
3
Will New Drugs Replace Transplants for Chronic Lymphocytic Leukaemia?新药会取代慢性淋巴细胞白血病的移植治疗吗？
J Clin Med. 2021 Jun 7;10(11):2516. doi: 10.3390/jcm10112516.
4
From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct.在慢性淋巴细胞白血病不断变化的格局中，从生物标志物到模型：进化还是灭绝。
Cancers (Basel). 2021 Apr 8;13(8):1782. doi: 10.3390/cancers13081782.
5
Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL.慢性淋巴细胞白血病中PI3K抑制的经验教训、挑战及未来治疗机会
Cancers (Basel). 2021 Mar 13;13(6):1280. doi: 10.3390/cancers13061280.